Difference between revisions of "Malignant solid neoplasm, RET-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
m |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 18: | Line 18: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https://doi.org/10.1016/s1470-2045(22)00541-1 Subbiah et al. 2022 (LIBRETTO-001)] | + | |[https://doi.org/10.1016/s1470-2045(22)00541-1 Subbiah et al. 2022 (LIBRETTO-001<sub>RET</sub>)] |
| − | {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | + | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" |
|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-357-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-357-1 <span style="color:white;">ESMO-MCBS (3)</span>]''' | ||
|- | |- | ||
| − | |} | + | |} --> |
|2017-12-04 to 2021-08-04 | |2017-12-04 to 2021-08-04 | ||
|style="background-color:#91cf61"|Phase 1/2 (RT) | |style="background-color:#91cf61"|Phase 1/2 (RT) | ||
| Line 34: | Line 34: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''LIBRETTO-001:''' Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. Epub 2022 Sep 12. [https://doi.org/10.1016/s1470-2045(22)00541-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36108661/ PubMed] [https://clinicaltrials.gov/study/NCT03157128 | + | # '''LIBRETTO-001<sub>RET</sub>:''' Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. Epub 2022 Sep 12. [https://doi.org/10.1016/s1470-2045(22)00541-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36108661/ PubMed] [https://clinicaltrials.gov/study/NCT03157128 NCT03157128] |
| − | [[Category:RET regimens]] | + | [[Category:Malignant solid neoplasm, RET-mutated regimens]] |
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Malignant solid neoplasm]] | [[Category:Malignant solid neoplasm]] | ||
| − | |||
Latest revision as of 11:50, 1 March 2024
1 regimens on this page
1 variants on this page
|
Advanced or metastatic disease, all lines of therapy
Selpercatinib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Subbiah et al. 2022 (LIBRETTO-001RET) | 2017-12-04 to 2021-08-04 | Phase 1/2 (RT) |
Note: this is the phase 2 recommended dosing.
References
- LIBRETTO-001RET: Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. Epub 2022 Sep 12. link to original article PubMed NCT03157128